OncoHost

Executive Summary

OncoHost is a precision oncology company headquartered in Binyamina, Israel, with a proprietary plasma-based proteomic AI platform called PROphet. By analyzing approximately 7,000 protein features from a single blood draw, PROphet generates a score that predicts patient benefit from PD-1/PD-L1 immunotherapy, enabling physicians to optimize first-line treatment decisions for cancers such as non-small-cell lung cancer and melanoma. The company was founded in 2020 and has reached commercial stage, offering a non-invasive test that addresses a critical unmet need in immunotherapy response prediction. Its technology has the potential to significantly improve patient outcomes by identifying responders and non-responders early, thereby reducing ineffective treatments and associated costs. OncoHost operates in the rapidly growing precision oncology and immunotherapy markets, which are projected to expand as more immunotherapies gain approval and the demand for companion diagnostics increases. With a focus on clinical utility and commercialization, the company is positioned to capture value in a space where few comparable products exist. While specific financial details and partnership announcements remain limited, OncoHost’s platform could serve as a key decision-support tool for oncologists worldwide, particularly as the use of immune checkpoint inhibitors continues to rise across multiple indications.

Upcoming Catalysts (preview)

• Q3 2026Publication of clinical validation study in a peer-reviewed journal75% success
• TBDFormation of strategic partnership with a major pharmaceutical company for co-development or distribution40% success
• Q4 2026Expansion of PROphet test to additional cancer indications (e.g., head and neck, bladder cancer)55% success